TLC Announces TLC599 Agreement with Endo SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

TLC Provides Corporate Update at Investor Conference Patient enrollment of EXCELLENCE pivotal trial reaches 98% SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 18, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage...

TLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599 Phase III clinical trial of TLC599 to recruit 500 patients with moderate to severe symptomatic knee osteoarthritis  Patients can receive two injections of placebo or drugPatient enrollment expected to...